^
BIOMARKER:

FGFR2 fusion

i
Other names: FGFR2, BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25, Fibroblast growth factor receptor
Entrez ID:
FGFR2 fusion
Cholangiocarcinoma
infigratinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
pemigatinib
Sensitive: A1 - Approval
FGFR2 fusion
Cholangiocarcinoma
TAS 120
Sensitive: B - Late Trials
FGFR2 fusion
Solid Tumor
infigratinib
Sensitive: C1 - Off-label
FGFR2 fusion
Glioma
infigratinib
Sensitive: C1 - Off-label
FGFR2 fusion
Gastric Cancer
infigratinib
Sensitive: C1 - Off-label
FGFR2 fusion
Breast Cancer
infigratinib
Sensitive: C1 - Off-label
FGFR2 fusion
HCC
infigratinib
Sensitive: C1 - Off-label
FGFR2 fusion
Cholangiocarcinoma
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 fusion
Gastric Cancer
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 fusion
Gastrointestinal Cancer
ARQ 087
Sensitive: C2 – Inclusion Criteria
FGFR2 fusion
Cholangiocarcinoma
erdafitinib
Sensitive: C3 – Early Trials
FGFR2 fusion
Solid Tumor
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 fusion
Urothelial Cancer
erdafitinib
Sensitive: C3 – Early Trials
FGFR2 fusion
Cholangiocarcinoma
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 fusion
Colon Cancer
Debio 1347
Sensitive: C3 – Early Trials
FGFR2 fusion
Cholangiocarcinoma
ICP-192
Sensitive: C3 – Early Trials